We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
176
DELISTED
Assertio
ASRT
$1.09M 0.04%
27,372
– –
XLV icon
177
State Street Health Care Select Sector SPDR ETF
XLV
$42.3B
$1.06M 0.04%
10,055
– –
SNR
178
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.03M 0.04%
256,398
– –
EIDX
179
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$1.01M 0.04%
20,000
– –
AXNX
180
DELISTED
Axonics, Inc. Common Stock
AXNX
$990K 0.04%
19,400
-8,700
-31% -$363K
KPTI icon
181
Karyopharm Therapeutics
KPTI
$44.6M
$960K 0.04%
+4,383
New +$1.07M
LKFT
182
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$929K 0.03%
6,543
– –
YARW
183
Yarrow Bioscience, Inc. Common Stock
YARW
$25.5M
$899K 0.03%
150
– –
ACIU icon
184
AC Immune
ACIU
$241M
$838K 0.03%
171,813
– –
GRFS
185
Grifois
GRFS
$5.38B
$822K 0.03%
47,373
– –
AERI
186
DELISTED
Aerie Pharmaceuticals
AERI
$785K 0.03%
66,688
– –
CRBP icon
187
Corbus Pharmaceuticals
CRBP
$179M
$744K 0.03%
13,783
+1,159
+9% +$210K
CHCT
188
Community Healthcare Trust
CHCT
$433M
$697K 0.03%
14,900
– –
UHT
189
Universal Health Realty Income Trust
UHT
$586M
$642K 0.02%
11,258
– –
CBAY
190
DELISTED
Cymabay Therapeutics
CBAY
$638K 0.02%
88,102
– –
NHI icon
191
National Health Investors
NHI
$3.62B
$605K 0.02%
10,038
– –
IMGN
192
DELISTED
Immunogen Inc
IMGN
$605K 0.02%
168,190
– –
RGNX icon
193
Regenxbio
RGNX
$677M
$597K 0.02%
21,700
– –
CYH icon
194
Community Health Systems
CYH
$423M
$497K 0.02%
117,735
– –
TPTX
195
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$496K 0.02%
5,677
– –
SPPI
196
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$468K 0.02%
114,670
– –
TCDA
197
DELISTED
Tricida, Inc. Common Stock
TCDA
$456K 0.02%
50,370
– –
CLSD
198
DELISTED
Clearside Biomedical
CLSD
$255K 0.01%
11,022
– –
ORKA
199
Oruka Therapeutics
ORKA
$5.89B
$143K 0.01%
2,705
– –
ALR
200
DELISTED
AlerisLife Inc
ALR
$123K ﹤0.01%
24,237
– –
6 7
8
9 10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.